Annals of Clinical Medicine and Medical Research (ISSN 2994-7464) | Volume 1, Issue 1 | Research Article | Open Access

Systematic review of the Bedaquiline, Pretomanid, and Linezolid (BPaL) Regimen for Drug- Resistant Tuberculosis

Takkellapati Tejaswini*

Nikhil Reddy Ravula1, Priyanka Thota2, Krishnamaneni Vamsi Krishna3, Arun Gajan Pradeep4, Yashwanth Vemoori5, Takkellapati Tejaswini6*

1Internal Medicine, Duke University Medical Centre, 905 S La Salle st,Durham,North Carolina, USA

2Siddhartha Medical College, NH-16 Service Road Beside NTR University of Health Sciences, India

3Department of Medicine, Katuri Medical College, India

4Department of Medicine, Kempegowda Institute of Medical Sciences, Bangalore, India

5Upmc Hillman Cancer Center, 732 S Millvale Ave,Pittsburgh, USA

6Mamata Medical College, Mamata Road, Khammam, Telangana, India

*Correspondence to: Takkellapati Tejaswini 

Fulltext PDF


Drug-resistant tuberculosis (TB) poses a significant global health challenge, demanding effective and innovative treatment strategies. The Bedaquiline, Pretomanid, and Linezolid (BPaL) regimen has emerged as a promising approach in the fight against multidrug-resistant and extensively drug-resistant TB. This systematic review synthesizes evidence from 30 selected studies to comprehensively evaluate the efficacy, safety, patient adherence, regional variations, and expert opinions surrounding the BPaL regimen. Our findings indicate that the BPaL regimen demonstrates promise in achieving positive treatment outcomes for drug-resistant TB patients. However, concerns regarding its safety profile, patient adherence, and regional variations emphasize the need for careful consideration and vigilant monitoring. Expert insights provide valuable guidance for optimizing the clinical use of the BPaL regimen. This review contributes to the ongoing discourse on effective treatment strategies for drug-resistant TB, with the goal of improving patient outcomes and global TB control efforts.


Bedaquiline; Pretomanid; Linezolid; Drug-resistant tuberculosis; BPaL regimen; Multidrug-resistant TB; Extensively drug-resistant TB; Efficacy; Safety; Patient adherence; Regional variations; Expert opinionsSystematic review; Treatment outcomes


Nikhil Reddy Ravula, Priyanka Thota, Krishnamaneni Vamsi Krishna, Arun Gajan Pradeep, Yashwanth Vemoori, Takkellapati Tejaswini. Systematic review of the Bedaquiline, Pretomanid, and Linezolid (BPaL) Regimen for Drug- Resistant Tuberculosis. Annal of Clin Med & Med Res. 2023;1(1):1-12.